Search results
Author(s):
Amish Raval
Added:
1 month ago
ACC 2025 - Principal results from autologous cell therapy in patients with heart failure with reduced ejection fraction (HFrEF) show favourable safety outcomes, however, the study did not meet its primary efficacy outcome using 6 minute walking rests as 3rd F-S tier.Dr Amish Raval (UW Health University Hospital Interventional Cardiology Clinic, WI, US) joins us onsite at ACC to discuss the…
View more
Author(s):
Tian-le Li
,
Mao-long Fu
,
Li-hong Wang
,
et al
Added:
7 hours ago
Author(s):
Tian-le Li
,
Mao-long Fu
,
Li-hong Wang
,
et al
Added:
1 month ago
Author(s):
Massimiliano Camilli
,
Luca Maggio
,
Lorenzo Tinti
,
et al
Added:
1 month ago
Advancements in Triglyceride-lowering Therapies
Video Series
Author(s):
Jason G Andrade
Added:
1 year ago
Tricuspid Regurgitation Therapy
Author(s):
Qiuyu Martin Zhu
,
Natalia Berry
Added:
1 year ago
Article
Author(s):
Fatin Fazrina Roslan
,
Yuexin Yu
,
Nurul Ain Nasim Mohd Yusof
,
et al
Added:
9 months ago
Author(s):
Christophe Leclercq
Added:
1 month ago
EHRA 2025 - Outcomes from cardiac resynchronization therapy (CRT) with MultiPoint pacing (MPP) to treat patients who are not responding to standard CRT show that MPP does not improve the conversion rate of non-responders to responders compared to standard CRT; however, a reduction in HF hospitalisation was seen in the group receiving MPP.Prof Christophe Leclercq (Centre Hospitalier Universitaire…
View more
Author(s):
Milind Y Desai
Added:
1 month ago
ACC 2025 - First-in-human results from MyPEAK-1 show Tn-201 treatment in adults with Mybpc3-associated hypertropic cardiomyopathy was feasible and safe.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at ACC 2025 to discuss phase Ib/2a results from the first-in-human, non-randomized study investigating the safety and early efficacy of Tn-201, an adeno-associated virus serotype 9 gene…
View more